As trade associations representing off-patent medicines and Active Pharmaceutical Ingredients (APIs) large, medium and small companies in Europe, directly providing highly skilled jobs, investing heavily in manufacturing R&D and accounting for 24% of API global production and 70% of prescription medicines supplied in Europe, this initiative demonstrates a comprehensive understanding of the complex challenges faced by the European pharmaceutical industry and addresses a pressing concern: the need for a coordinated and robust approach to safeguard the medicine supply chain in Europe.